Design Therapeutics is a biotechnology company developing a new class of therapies based on its platform of GeneTAC™ gene targeted chimera small molecules. The company’s GeneTAC™ molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its lead GeneTAC™ small molecule, DT-216, in development for patients with Friedreich ataxia, the company is advancing programs in Fuchs endothelial corneal dystrophy and myotonic dystrophy type-1. Discovery efforts for multiple other serious degenerative disorders caused by nucleotide repeat expansions are also underway, including for fragile X syndrome, spinocerebellar ataxias, Huntington disease, spinobulbar muscular atrophy, and C9orf72-amyotrophic lateral sclerosis/frontotemporal dementia. For more information, please visit designtx.com.
Company profile
Ticker
DSGN
Exchange
Website
CEO
João Siffert
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
823929248
DSGN stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
25 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
S-8
Registration of securities for employees
19 Mar 24
10-K
2023 FY
Annual report
19 Mar 24
8-K
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
19 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024
13 Nov 23
8-K
Departure of Directors or Certain Officers
25 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
Latest ownership filings
4
John P. Schmid
25 Mar 24
4
Heather A. Berger
25 Mar 24
3
Jae B. Kim
20 Mar 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
Cormorant Asset Management, LP
14 Feb 24
SC 13G/A
STATE STREET CORP
23 Jan 24
4
Julie Burgess
5 Jan 24
4
Sean Jeffries
5 Jan 24
4
RODNEY W LAPPE
5 Dec 23
4
Aseem Z. Ansari
5 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 27.94 mm | 27.94 mm | 27.94 mm | 27.94 mm | 27.94 mm | 27.94 mm |
Cash burn (monthly) | (no burn) | 1.21 mm | 6.27 mm | 6.87 mm | 4.84 mm | 5.07 mm |
Cash used (since last report) | n/a | 8.38 mm | 43.29 mm | 47.41 mm | 33.43 mm | 34.99 mm |
Cash remaining | n/a | 19.56 mm | -15.35 mm | -19.47 mm | -5.48 mm | -7.05 mm |
Runway (months of cash) | n/a | 16.1 | -2.4 | -2.8 | -1.1 | -1.4 |
Institutional ownership, Q3 2023
83.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 90 |
Opened positions | 14 |
Closed positions | 25 |
Increased positions | 26 |
Reduced positions | 38 |
13F shares | Current |
---|---|
Total value | 77.30 bn |
Total shares | 47.06 mm |
Total puts | 126.30 k |
Total calls | 107.40 k |
Total put/call ratio | 1.2 |
Largest owners | Shares | Value |
---|---|---|
SR One Capital Fund I Aggregator | 6.53 mm | $54.37 mm |
SR One Capital Management | 6.53 mm | $15.40 bn |
Logos Global Management | 5.03 mm | $11.88 bn |
Irrevocable Trust #1 dated April 22, 2019 Light | 3.83 mm | $82.09 mm |
Irrevocable Trust #1 dated April 22, 2019 Star | 3.83 mm | $82.09 mm |
Citadel Advisors | 2.70 mm | $6.37 bn |
RTW Investments | 2.51 mm | $5.93 bn |
BLK Blackrock | 2.40 mm | $5.67 bn |
Baker Bros. Advisors | 1.50 mm | $3.54 bn |
Tang Capital Management | 1.35 mm | $3.19 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Mar 24 | Heather Behanna | Common Stock | Buy | Acquire P | No | No | 3.7429 | 1,300 | 4.87 k | 1,300 |
25 Mar 24 | Schmid John P. | Common Stock | Buy | Acquire P | Yes | No | 3.74 | 17,809 | 66.61 k | 26,965 |
22 Mar 24 | Schmid John P. | Common Stock | Buy | Acquire P | Yes | No | 3.6187 | 9,156 | 33.13 k | 9,156 |
2 Jan 24 | Sean Jeffries | Stock Option Common Stock | Grant | Acquire A | No | No | 2.54 | 350,000 | 889.00 k | 350,000 |
2 Jan 24 | Julie Burgess | Stock Option Common Stock | Grant | Acquire A | No | No | 2.54 | 110,000 | 279.40 k | 110,000 |
News
Design Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
26 Mar 24
RBC Capital Reiterates Sector Perform on Design Therapeutics, Maintains $4 Price Target
20 Mar 24
Wedbush Reiterates Neutral on Design Therapeutics, Maintains $5 Price Target
20 Mar 24
Earnings Preview For Design Therapeutics
18 Mar 24
12 Health Care Stocks Moving In Friday's Pre-Market Session
9 Feb 24